Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00193219
- Locations
- 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸Jackson Oncology Associates, Jackson, Mississippi, United States
🇺🇸Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00176774
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 60
- Registration Number
- NCT00176462
- Locations
- 🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 498
- Registration Number
- NCT00165178
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-08-18
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT00155883
- Locations
- 🇨🇳
Department of Oncology, Nationa Taiwan University Hospital, Taipei, Taiwan
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00139243
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00139230
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00136435
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇨🇦Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2018-09-17
- Target Recruit Count
- 23
- Registration Number
- NCT00133991
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00126191
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.